Vivos (RDGL) Shareholder's Equity Growth (5y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Vivos | - | - | -3,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 120.26% |
| Sep 30, 2025 | 35.14% |
| Jun 30, 2025 | 40.19% |
| Mar 31, 2025 | 35.38% |
| Dec 31, 2024 | 28.11% |
| Sep 30, 2024 | 24.59% |
| Jun 30, 2024 | 26.98% |
| Mar 31, 2024 | 26.58% |
| Dec 31, 2023 | 28.10% |
| Sep 30, 2023 | 15.35% |
| Jun 30, 2023 | 16.62% |
| Mar 31, 2023 | 17.90% |
| Dec 31, 2022 | 19.03% |
| Sep 30, 2022 | 20.42% |
| Jun 30, 2022 | 15.54% |
| Mar 31, 2022 | 15.79% |
| Dec 31, 2021 | 19.98% |
| Sep 30, 2021 | 15.61% |
| Jun 30, 2021 | 15.68% |
| Mar 31, 2021 | 15.92% |
| Dec 31, 2020 | 14.90% |
| Sep 30, 2020 | 37.01% |
| Jun 30, 2020 | 44.99% |
| Mar 31, 2020 | 43.21% |
| Dec 31, 2019 | 40.69% |
| Sep 30, 2019 | 33.88% |
| Jun 30, 2019 | 33.78% |
| Mar 31, 2019 | 35.45% |
| Dec 31, 2018 | 36.27% |
| Sep 30, 2018 | -32.53% |
| Jun 30, 2018 | -5.75% |
| Mar 31, 2018 | 9.28% |
| Dec 31, 2017 | 15.43% |
| Sep 30, 2017 | 9.63% |
| Jun 30, 2017 | -19.57% |
| Mar 31, 2017 | -22.27% |
| Dec 31, 2016 | 8.98% |
| Sep 30, 2016 | -39.24% |
| Jun 30, 2016 | -42.29% |
| Dec 31, 2015 | -37.05% |